Akari Therapeutics Business Summary

Akari Therapeutics Plc (AKTX) is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements, research grants, and potential future milestone payments as it advances its therapeutic pipeline toward commercialization. Following its 2024 merger with Peak Bio, the company operates through two primary business segments: Oncology, focused on its proprietary antibody-drug conjugate (ADC) platform targeting the spliceosome (lead candidate AKTX-101), and Autoimmune/Inflammatory diseases, centered on its bispecific C5 complement and LTB4 inhibitor, nomacopan. Akari competes directly with established players such as Apellis Pharmaceuticals, Annexon, and Omeros Corporation, positioning itself as a specialist in bifunctional therapies designed to address high unmet needs in rare diseases like HSCT-TMA and various solid tumors. The company is led by President and CEO Abizer Gaslightwala, who assumed the role in April 2025 and brings over 25 years of industry experience from senior leadership positions at Jazz Pharmaceuticals, Amgen, and Pfizer. The leadership team also includes Interim CFO Kameel D. Farag, formerly of Aspen Neuroscience and Ionis Pharmaceuticals, and Chairman Hoyoung Huh, MD, PhD, the founder of Peak Bio and a veteran healthcare entrepreneur. Akari’s strategic direction is further supported by a board featuring notable figures such as Dr. Samir R. Patel and Dr. Sara Hurvitz, alongside a sophisticated investor base that has historically included institutional backers like Venrock, Foresite Capital, and Vivo Capital.